Dissociation of β-amyloid from lipoprotein in cerebrospinal fluid from Alzheimer's disease accelerates β-amyloid-42 assembly

Journal of Neuroscience Research

Volumn 89, Issue 6, 2011, Pages 815-821

  Takamura, Ayumi ^a,b   Kawarabayashi, Takeshi ^b   Yokoseki, Tatsuki ^c   Shibata, Masao ^c   Morishima Kawashima, Maho ^d   Saito, Yuko ^e   Murayama, Shigeo ^e   Ihara, Yasuo ^f   Abe, Koji ^g   Shoji, Mikio ^b   Michikawa, Makoto ^a   Matsubara, Etsuro ^a,b  

^a NATIONAL CENTER FOR GERIATRICS AND GERONTOLOGY   (Japan)

^b HIROSAKI UNIVERSITY   (Japan)

^c Immunas Pharma Incorporation   (Japan)

^d HOKKAIDO UNIVERSITY   (Japan)

^e TOKYO METROPOLITAN INSTITUTE OF GERONTOLOGY   (Japan)

^f DOSHISHA UNIVERSITY   (Japan)

^g OKAYAMA UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

A ; Alzheimer's disease; Lipoprotein; Monomer; Oligomer

Indexed keywords

AMYLOID BETA PROTEIN; AMYLOID BETA PROTEIN ANTIBODY; AMYLOID BETA PROTEIN[1-40]; AMYLOID BETA PROTEIN[1-42]; LIPOPROTEIN; MONOCLONAL ANTIBODY; MONOMER; OLIGOMER;

AGED; ALZHEIMER DISEASE; ARTICLE; CENTRAL NERVOUS SYSTEM; CEREBROSPINAL FLUID; CLINICAL ARTICLE; COGNITIVE DEFECT; CONTROLLED STUDY; DISSOCIATION; ENTORHINAL CORTEX; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FRONTAL CORTEX; GEL PERMEATION CHROMATOGRAPHY; HUMAN; HUMAN TISSUE; MALE; NERVE CELL NECROSIS; NEUROFIBRILLARY TANGLE; PRIORITY JOURNAL; PROTEIN ASSEMBLY; PROTEIN CONFORMATION; PROTEIN PROTEIN INTERACTION;

AGED; AGED, 80 AND OVER; ALZHEIMER DISEASE; AMYLOID BETA-PEPTIDES; ANALYSIS OF VARIANCE; BRAIN; CASE-CONTROL STUDIES; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMANS; LIPOPROTEINS; MALE; MIDDLE AGED; PEPTIDE FRAGMENTS;

EID: 79954625121     PISSN: 03604012     EISSN: 10974547     Source Type: Journal    
DOI: 10.1002/jnr.22615     Document Type: Article

References (37)

1. 1-42 into globular neurotoxins. Biochemistry 42: 12749-12760.
2. Cleary JP, Walsh DM, Hofmeister JJ, Shankar GM, Kuskowski MA, Selkoe DJ, Ashe KH. 2005. Natural oligomers of the amyloid-β protein specifically disrupt cognitive function. Nat Neurosci 8: 79-84.
3. Enya M, Morishima-Kawashima M, Yoshimura M, Shinkai Y, Kusui K, Khan K, Games D, Schenk D, Sugihara S, Yamaguchi H, Ihara Y. 1999. Appearance of sodium dodecyl sulfate-stable amyloid beta-protein (Abeta) dimer in the cortex during aging. Am J Pathol 154: 271-279.
4. Fagan AM, Mintun MA, Mach RH, Lee SY, Dence CS, Shah AR, LaRossa GN, Spinner ML, Klunk WE, Mathis CA, DeKosky ST, Morris JC, Holtzman DM. 2006. Inverse relation between in vivo amyloid imaging load and cerebrospinal fluid Abeta42 in humans. Ann Neurol 59: 512-519.
5. Fukumoto H, Tokuda T, Kasai T, Ishigami N, Hidaka H, Kondo M, Allsop D, Nakagawa M. 2010. High-molecular-weight beta-amyloid oligomers are elevated in cerebrospinal fluid of Alzheimer patients. FASEB J 24: 2716-2726.
6. Funato H, Enya M, Yoshimura M, Morishima-Kawashima M, Ihara Y. 1999. Presence of sodium dodecyl sulfate-stable amyloid beta-protein dimers in the hippocampus CA1 not exhibiting neurofibrillary tangle formation. Am J Pathol 155: 23-28.
7. Georganopoulou DG, Chang L, Nam JM, Thaxton CS, Mufson EJ, Klein WL, Mirkin CA. 2005. Nanoparticle-based detection in cerebral spinal fluid of a soluble pathogenic biomarker for Alzheimer's disease. Proc Natl Acad Sci U S A 102: 2273-2276.
8. Geula C, Wu CK, Saroff D, Lorenzo A, Yuan M, Yankner BA. 1998. Aging renders the brain vulnerable to amyloid beta-protein neurotoxicity. Nat Med 4: 827-831.
9. Gong JS, Sawamura N, Zou K, Sakai J, Yanagisawa K, Michikawa M. 2002. Amyloid beta-protein affects cholesterol metabolism in cultured neurons: implications for pivotal role of cholesterol in the amyloid cascade. J Neurosci Res 70: 438-446.
10. Gong Y, Chang L, Viola KL, Lacor PN, Lambert MP, Finch CE, Krafft GA, Klein WL. 2003. Alzheimer's disease-affected brain: presence of oligomeric Aβ ligands (ADDLs) suggests a molecular basis for reversible memory loss. Proc Natl Acad Sci U S A 100: 10417-10422.
11. Hass C, Selkoe DJ. 2007. Soluble protein oligomers in neurodegeneration: lessons from the Alzheimer's amyloid β-peptide. Nat Rev Mol Cell Biol 8: 101-112.
12. Ikeda T, Ono K, Elashoff D, Condron MM, Noguchi-Shinohara M, Yoshita M, Teplow DB, Yamada M. 2010. Cerebrospinal fluid from Alzheimer's disease patients promotes amyloid beta-protein oligomerization. J Alzheimers Dis 21: 81-86.
13. Katsuno T, Morishima-Kawashima M, Saito Y, Yamanouchi H, Ishiura S, Murayama S, Ihara Y. 2005. Independent accumulations of tau and amyloid beta-protein in the human entorhinal cortex. Neurology 64: 687-692.
14. Kayed R, Pensalfini A, Margol L, Sokolov Y, Sarsoza F, Head E, Hall J, Glabe C. 2009. Annular protofibrils are a structurally and functionally distinct type of amyloid oligomer. J Biol Chem 284: 4230-4237.
15. Klein WL, Krafft GA, Finch CE. 2001. Targeting small Abeta oligomers: the solution to an Alzheimer's disease conundrum? Trends Neurosci 24: 219-224.
16. Klunk WE, Engler H, Nordberg A, Wang Y, Blomqvist G, Holt DP, Bergström M, Savitcheva I, Huang GF, Estrada S, Ausén B, Debnath ML, Barletta J, Price JC, Sandell J, Lopresti BJ, Wall A, Koivisto P, Antoni G, Mathis CA, Långström B. 2004. Imaging brain amyloid in Alzheimer's disease with Pittsburgh compound-B. Ann Neurol 55: 306-319.
17. Koudinov AR, Koudinova NV, Kumar A, Beavis RC, Ghiso J. 1996. Biochemical characterization of Alzheimer's soluble amyloid beta protein in human cerebrospinal fluid: association with high density lipoproteins. Biochem Biophys Res Commun 223: 592-597.
18. Lacor PN, Buniel MC, Chang L, Fernandez SJ, Gong Y, Viola KL, Lambert MP, Velasco PT, Bigio EH, Finch CE, Krafft GA, Klein WL. 2004. Synaptic targeting by Alzheimer's-related amyloid β oligomers. J Neurosci 24: 10191-10200.
19. 1-42 are potent central nervous system neurotoxins. Proc Natl Acad Sci U S A 95: 6448-6453.
20. Lashuel HA, Hartley D, Petre BM, Walz T, Lansbury PTJr. 2002. Neurodegenerative disease: amyloid pores from pathogenic mutations. Nature 418: 291.
21. Lesné S, Koh MT, Kotilinek L, Kayed R, Glabe CG, Yang A, Gallagher M, Ashe KH. 2006. A specific amyloid-beta protein assembly in the brain impairs memory. Nature 440: 352-357.
22. Lin H, Bhatia R, Lal R. 2001. Amyloid beta protein forms ion channels: implications for Alzheimer's disease pathophysiology. FASEB J 15: 2433-2444.
23. Matsubara E, Ghiso J, Frangione B, Amari M, Tomidokoro Y, Ikeda Y, Harigaya Y, Okamoto K, Shoji M. 1999. Lipoprotein-free amyloidogenic peptides in plasma are elevated in patients with sporadic Alzheimer's disease and Down's syndrome. Ann Neurol 45: 537-541.
24. Matsubara E, Sekijima Y, Tokuda T, Urakami K, Amari M, Shizuka-Ikeda M, Tomidokoro Y, Ikeda M, Kawarabayashi T, Harigaya Y, Ikeda S, Murakami T, Abe K, Otomo E, Hirai S, Frangione B, Ghiso J, Shoji M. 2004. Soluble Abeta homeostasis in AD and DS: impairment of anti-amyloidogenic protection by lipoproteins. Neurobiol Aging 25: 833-841.
25. Michikawa M, Gong JS, Fan QW, Sawamura N, Yanagisawa K. 2001. Anovel action of alzheimer's amyloid beta-protein (Abeta): oligomeric Abeta promotes lipid release. J Neurosci 21: 7226-7235.
26. Noguchi A, Matsumura S, Dezawa M, Tada M, Yanazawa M, Ito A, Akioka M, Kikuchi S, Sato M, Ideno S, Noda M, Fukunari A, Muramatsu S, Itokazu Y, Sato K, Takahashi H, Teplow DB, Nabeshima Y, Kakita A, Imahori K, Hoshi M. 2009. Isolation and characterization of patient-derived, toxic, high mass amyloid beta-protein (Abeta) assembly from Alzheimer disease brains. J Biol Chem 284: 32895-32905.
27. Quist A, Doudevski I, Lin H, Azimova R, Ng D, Frangione B, Kagan B, Ghiso J, Lal R. 2005. Amyloid ion channels: a common structural link for protein-misfolding disease. Proc Natl Acad Sci U S A 102: 10427-10432.
28. Schmechel DE, Saunders AM, Strittmatter WJ, Crain BJ, Hulette CM, Joo SH, Pericak-Vance MA, Goldgaber D, Roses AD. 1993. Increased amyloid beta-peptide deposition in cerebral cortex as a consequence of apolipoprotein E genotype in late-onset Alzheimer disease. Proc Natl Acad Sci U S A 90: 9649-9653.
29. Selkoe DJ. 2002. Alzheimer's disease is a synaptic failure. Science 298: 789-791.
30. Shankar GM, Li S, Mehta TH, Garcia-Munoz A, Shepardson NE, Smith I, Brett FM, Farrell MA, Rowan MJ, Lemere CA, Regan CM, Walsh DM, Sabatini BL, Selkoe DJ. 2008. Amyloid-betaprotein dimers isolated directly from Alzheimer's brains impairsynaptic plasticity and memory. Nat Med 14: 837-842.
31. Tanzi RE, Bertram L. 2001. New frontiers in Alzheimer's disease genetics. Neuron 32: 181-184.
32. Wahrle SE, Jiang H, Parsadanian M, Hartman RE, Bales KR, Paul SM, Holtzman DM. 2005. Deletion of Abca1 increases Abeta deposition in the PDAPP transgenic mouse model of Alzheimer disease. J Biol Chem 280: 43236-43242.
33. Wahrle SE, Jiang H, Parsadanian M, Kim J, Li A, Knoten A, Jain S, Hirsch-Reinshagen V, Wellington CL, Bales KR, Paul SM, Holtzman DM. 2008. Overexpression of ABCA1 reduces amyloid deposition in the PDAPP mouse model of Alzheimer disease. J Clin Invest 118: 671-682.
34. Walsh DM, Klyubin I, Fadeeva JV, Cullen WK, Anwyl R, Wolfe MS, Rowan MJ, Selkoe DJ. 2002. Naturally secreted oligomers of amyloid β protein potently inhibit hippocampal long-term potentiation in vivo. Nature 16: 535-539.
35. Wellington CL. 2004. Cholesterol at the crossroads: Alzheimer's disease and lipid metabolism. Clin Genet 66: 1-16.
36. Yamada K, Yabuki C, Seubert P, Schenk D, Hori Y, Ohtsuki S, Terasaki T, Hashimoto T, Iwatsubo T. 2009. Abeta immunotherapy: intracerebral sequestration of Abeta by an anti-Abeta monoclonal antibody 266 with high affinity to soluble Abeta. J Neurosci 29: 11393-11398.
37. Zou K, Gong JS, Yanagisawa K, Michikawa M. 2002. A novel function of monomeric amyloid beta-protein serving as an antioxidant molecule against metal-induced oxidative damage. J Neurosci 22: 4833-4841.